User profiles for J. F. Merola
Joseph F. Merola, MD MMScHarvard Medical School, Brigham and Women's Hospital Verified email at partners.org Cited by 10199 |
2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
…, P Marchetta, PJ Mease, JF Merola… - Journal of Psoriasis …, 2019 - journals.sagepub.com
Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic
treatment of psoriatic arthritis (PsA), as a collaboration between the American College …
treatment of psoriatic arthritis (PsA), as a collaboration between the American College …
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Psoriasis is one of the most common chronic inflammatory skin diseases, affecting 3% of the
world’s population, and approximately one-third of patients with psoriasis will eventually …
world’s population, and approximately one-third of patients with psoriasis will eventually …
Raynaud's phenomenon: pathogenesis and management
R Bakst, JF Merola, AG Franks Jr, M Sanchez - Journal of the American …, 2008 - Elsevier
Raynaud's phenomenon is a common clinical disorder for which patients frequently seek the
expertise and care of dermatologists. It is manifested by recurrent vasospasm of the fingers …
expertise and care of dermatologists. It is manifested by recurrent vasospasm of the fingers …
[HTML][HTML] Tofacitinib or adalimumab versus placebo for psoriatic arthritis
…, D van der Heijde, JF Merola… - … England Journal of …, 2017 - Mass Medical Soc
Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis …
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis …
[HTML][HTML] Trial of upadacitinib and adalimumab for psoriatic arthritis
Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind …
Background There is an unmet need for a treatment for psoriasis that results in complete skin
clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that …
clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that …
[HTML][HTML] Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …
[HTML][HTML] Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised …
JF Merola, R Landewé, IB McInnes, PJ Mease… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
[HTML][HTML] Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
R Furie, VP Werth, JF Merola… - The Journal of …, 2019 - Am Soc Clin Investig
BACKGROUND. Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines
convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a …
convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a …
[HTML][HTML] From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis
…, AM Mandelin, MA Menter, JF Merola… - Journal of the American …, 2017 - Elsevier
Background An urgent need exists in the United States to establish treatment goals in
psoriasis. Objective We aim to establish defined treatment targets toward which clinicians and …
psoriasis. Objective We aim to establish defined treatment targets toward which clinicians and …